High Dose BAYA1040 CR: a Long Term Extension Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01355367

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01355367
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01355367. Non-randomized; no masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2011-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
High Dose BAYA1040 CR: a Long Term Extension Study
Condition
Hypertension
Intervention (Drug)
Nifedipine (Adalat, BAYA1040)
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01355367
Content hash
8ceffb70dd414e08396ef217563050012c2172e06256f62b5ec835b133931436